Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

February 25, 2019

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions

Neoplasms

Interventions

DRUG

GSK3377794

GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.

DRUG

Pembrolizumab

Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.

DRUG

Fludarabine

Fludarabine will be used as a lymphodepleting chemotherapy.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as a lymphodepleting chemotherapy.